替格瑞洛药代动力学及血药浓度测定方法的研究现状  

Research progress of ticagrelor pharmacokinetics and blood concentration determination methods

作　　者：张晓蕊 孙雅晴 赵晴 杨秀岭[1] ZHANG Xiao-rui;SUN Ya-qing;ZHAO Qing;YANG Xiu-ling(Department of Pharmacy,The Second Hospital of Hebei Medical University,Shijiazhuang 050000,Hebei Province,China)

机构地区：[1]河北医科大学第二医院药学部,河北石家庄050000

出　　处：《中国临床药理学杂志》2022年第23期2902-2906,共5页The Chinese Journal of Clinical Pharmacology

摘　　要：替格瑞洛可阻断血小板的活化和聚集,用于预防急性冠状动脉综合征和既往心肌梗死患者的血栓事件,其临床应用受制于不良事件的发生及个体差异。因此,替格瑞洛的血药浓度测定和药代动力学研究对于其临床合理应用十分必要。液相色谱-质谱联用技术是目前测定替格瑞洛及其活性代谢产物最广泛的检测方法之一。本综述就替格瑞洛的药代动力学特点及血药浓度测定方法进行概述,旨在为替格瑞洛治疗药物监测的开展提供参考。Ticagrelor can block the activation and aggregation of thrombocytes,and is used to prevent thrombotic events in patients with acute coronary syndrome and previous myocardial infarction.Its clinical application is subject to the occurrence of adverse events and the individual difference.Therefore,the blood concentration monitoring and pharmacokinetic research of ticagrelor are necessary for its reasonable clinical requirement.LC-MS technology is presently one of the most extensively detection methods for the determination of ticagrelor and its active metabolites.This review summarizes the pharmacokinetic characteristics of ticagrelor and the methods for determination of blood concentration,aiming to provide a reference for the development of ticagrelor therapeutic drug.

关 键 词：替格瑞洛 血药浓度测定 药物代动力学 

分 类 号：R972[医药卫生—药品]